Drugs / SNE-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06995625 | Jun 2026 → Mar 2027 expected | ischemic stroke | S&Ebio Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNE-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06995625 ↗ |
| Modality | Other / unclassified | “allogeneic Wharton's jelly-mesenchymal stem cell-derived extracellular vesicles (EVs)” NCT06995625 ↗ |
| Route | Intravenous | “SNE-101 will be administered intravenously once a day for 5 days.” NCT06995625 ↗ |